Sodium Glycididazole for Injection

Glycidibizole sodium is a sensitizer for tumor radiotherapy. It belongs to the nitroimidazole class of compounds. It can fix the damage caused by radiation to the DNA of tumor hypoxic cells and inhibit the repair of DNA damage, thereby increasing the sensitivity of tumor hypoxic cells to radiation. Toxicology study: Repeated administration toxicity: The main toxic reactions of long-term intravenous infusion of this product in Beagle dogs are nausea, vomiting, mild salivation, slight muscle tremors, etc., and may cause death of animals due to blood system and central nervous system disorders. The dose without toxic reaction is 60mg/kg/day (about 7.5 times the clinically recommended dose based on body surface area conversion).

The main ingredient of this product is sodium glycidazole.

Radiosensitizers are suitable for patients undergoing radiotherapy for solid tumors such as head and neck tumors, esophageal cancer, and lung cancer.

Intravenous drip. 800 mg/m2 per body surface area, add to 100 ml of saline before radiotherapy, shake well, and drip within 30 minutes. Perform radiotherapy within 60 minutes after administration. It is recommended to take the drug every other day and three times a week during radiotherapy.

During use, slight elevation of GPT and GOT, palpitations, sinus tachycardia, and mild ST segment changes may occur. Occasionally, itching, rash, nausea, and vomiting may occur.

It is contraindicated for patients with severe abnormalities in liver, kidney and heart function.

Drug interaction studies have not been performed.

Sealed, store in a cool, dark and dry place.

0.25g

Shandong Luye Pharmaceutical Co., Ltd.

• Founded in:

  1994-06-08

• Address:

  No. 15, Chuangye Road, High-tech Zone, Yantai City, Shandong Province

• Tax NO.:

  913706001650849788

• Registered Funds:

  2,031.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view